Therapeutic | Rontalizumab |
Target | IFNA1 |
Heavy Chain | EVQLVESGGGLVQPGGSLRLSCATSGYTFTEYIIHWVRQAPGKGLEWVASINPDYDITNYNQRFKGRFTISLDKSKRTAYLQMNSLRAEDTAVYYCASWISDFFDYWGQGTLVTVSS |
Light Chain | DIQMTQSPSSLSASVGDRVTITCRASQSVSTSSYSYMHWYQQKPGKAPKVLISYASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSWGIPRTFGQGTKVEIK |
100% seqID Fv Structure | 4z5r [Fvs: BA, KJ, ML, QP, SR, UT, WV, ZY] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 4z5r [Fvs: BA, KJ, ML, QP, SR, UT, WV, ZY] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G2 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Discontinued |
Recorded Developmental Technology | na |
INN Year Proposed | 2009 |
INN Year Recommended | 2010 |
Companies Involved | Chugai Pharmaceutical, Genentech |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Systemic lupus erythematosus |
Notes |